GlassScriptPhysician profile
Kenneth G Zierer
NPI 1417978883
$8,143.81
in general payments reported to CMS, 2019-2025
32 companies · $1,377 in 2025
The $1,377 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,223 · 2020: $608 · 2021: $737 · 2022: $1,542 · 2023: $1,300 · 2024: $1,357 · 2025: $1,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,034.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,416.61 | 2019-2025 | Linzess, Viberzi, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $881.22 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Intercept Pharmaceuticals, INC. | $773.66 | 2019-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $584.90 | 2019-2024 | Linzess |
| Madrigal Pharmaceuticals | $513.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $491.95 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $469.41 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $404.12 | 2019-2025 | |
| Janssen Biotech, INC. | $382.21 | 2019-2024 | Stelara, Tremfya, Simponi |
| Phathom Pharmaceuticals, INC. | $230.77 | 2024-2025 | Voquezna |
| Allergan, INC. | $224.79 | 2019-2020 | |
| Ardelyx, INC. | $213.29 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $173.62 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Braintree Laboratories, INC. | $155.03 | 2019-2025 | Suflave, Sutab |
| Shionogi INC | $147.67 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $142.32 | 2024-2025 | Iqirvo |
| Lilly USA, LLC | $134.95 | 2024 | Omvoh |
| Pfizer INC. | $124.35 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $121.01 | 2025 | Neffy |
| E.R. Squibb & Sons, L.L.C. | $119.46 | 2022 | |
| Qol Medical, LLC | $90.14 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $69.85 | 2021-2022 | |
| Vivus LLC | $52.59 | 2025 | Qsymia, Pancreaze |
| Novo Nordisk INC | $50.83 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $40.67 | 2022-2024 | Rebyota |
| Merck Sharp & Dohme LLC | $29.32 | 2021-2022 | |
| Intra-Sana Laboratories | $24.37 | 2022 | |
| Exact Sciences Corporation | $18.14 | 2024 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $17.75 | 2025 | Zenpep |
| Genzyme Corporation | $17.45 | 2024 | |
| Ethicon US, LLC | $16.86 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $10.60 | 2023 | Clips (Need Marketed Device Name) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Zierer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.